Filtering out self-like neoantigens improves immune response to cancer vaccines

Guilhem Richard, Bethany Biron, Christine Boyle, Matthew Ardito, Leonard Moise, William Martin, Gad Berdugo, Anne S. De Groot

Prepared by:

Guilhem Richard, Ph.D.


grichard@epivaxonco.com

Lead Computational Immunologist EpiVax Oncology, Inc.

Prepared for:


AACR Annual Meeting 2019

Cancer Vaccines and Intratumoral Immunomodulation Minisymposium Sunday Mar. 31st, 2019 Atlanta, Georgia, USA Who are we? EpiVax Oncology, est. 2017



- EpiVax Oncology, Inc. is company created in 2017 by EpiVax, Inc.
- EpiVax, Inc. is a 20-year-old, privately held immunoinformatics biotech.

What do we do? Use commercial-grade tools to design precision cancer immunotherapies




Talk Overview? It's all about finding and removing Treg neo-epitopes.


- Some MHC II T cell epitopes are recognized by Tregs and reduce vaccine efficacy.
- In this presentation I will show you that:
 - 1. We find self-like (i.e. putative Treg) neo-epitopes in cancer mutanomes and remove them from vaccines.
 - 2. We design highly immunogenic vaccines by <u>precisely</u> selecting MHC I and MHC II effector neo-epitopes.
 - 3. Some self-like MHC II neo-epitopes reduce vaccine immunogenicity by 5fold.
- Inclusion of Treg neo-epitopes in cancer immunotherapies may be a cause for lack of efficacy.

Some T cell epitopes may engage Tregs. Achieving the right balance between Teff and Treg epitopes is important.

Epitopes can be either effector or regulatory



Inclusion of Treg epitopes may hinder vaccine efficacy



Good vaccines: balance shifted toward inflammation

Poor vaccines: balance shifted towards regulation


How to eliminate Treg responses?


We identified Treg epitopes in pathogens. Can lessons learned from infectious disease be translated to oncology?

In silico tools help us identify immunosuppressive T cell epitopes.

Moise, Hum Vaccin Immunother 2013








Liu, Hum Vaccin Immunother 2015



Finding the right neo-epitopes to include in personalized immunotherapies remains a challenge.



Barrier to success

Which neo-epitopes should be included in personalized immunotherapies?

Traditional considerations:

- Variant Expression
- Variant Clonality
- Class I MHC binding (CD8 T cells)


Additional novel considerations:

- Class II MHC binding (CD4 T cells)
- Type of T cell response (Teff or Treg)




- Background
- Can our *in silico* platform generate immunogenic neo-epitopebased vaccines?
- Can certain neo-epitopes negatively affect the outcome of immunotherapies?
- Summary and next steps

We precisely designed a new CT26 vaccine enriched for Teff content and with reduced risk of engaging Tregs



UNPUBLISHED – DO NOT POST

Immunization of naïve Balb/c mice with our CT26 vaccine induced strong IFN γ ELISpot responses




UNPUBLISHED – DO NOT POST

Flow cytometry confirmed that our CT26 vaccine stimulated multifunctional CD4+ and CD8+ T cells


IFNγ **ELISpot** Results Protocol p < 0.001 12,000s.c. s.c. sacrifice s.c. 10,000 IFNg+ T cells SFC/10⁶ Above Background Day 35 Balb/C Day 0 Day 14 Day 28 8,000-Saline + Poly-ICLC 6,000-N = 8 4,000-Ancer™ vaccine + Poly-ICLC N = 8 2,000n Prime + boost x2, bi-weekly Control Ancer Mean + SEM

Strong neo-epitope responses



Multifunctional CD4+/CD8+ response

Preliminary results show a 42% reduction in tumor burden with our CT26 vaccine (unoptimized dosing schedule)



N = 12 mice per group


Ancer[™] vaccine alone reduces median CT26 tumor burden by 42% at day 22. Additional efficacy studies are ongoing.

3/19/2019

Outline and preliminary conclusions


- Background
- Can our *in silico* platform generate immunogenic neo-epitopebased vaccines?
 YES
- Can certain neo-epitopes negatively affect the outcome of immunotherapies?
- Summary and next steps

We selected 10 MHC II "self-like" CT26 neo-epitopes. We hypothesize these may be Treg epitopes.



UNPUBLISHED – DO NOT POST

Co-administration of CT26 self-like neo-epitopes with our immunogenic vaccine diminished IFNγ ELISpot responses by 5-fold



3/19/2019



- Background
- Can our *in silico* platform we generate immunogenic neoepitope-based vaccines? YES
- Can certain neo-epitopes negatively affect the outcome of immunotherapies?
 YES
- Summary and next steps

Summary

- Not all neo-epitopes are created equal!
- Some neo-epitopes may suppress immune responses due to their homology with self-sequences.
- We designed a new highly immunogenic CT26 neoantigen-based vaccine enhanced for both CD4 and CD8 T effector content and devoid of selflike epitopes.
- Our vaccine induced strong IFNγ ELISpot responses and multifunctional CD4+ and CD8+ T cell responses.
- Co-administration of self-like MHC II neo-epitopes with our vaccine reduced its immunogenicity by 5-fold.

Next Steps

- Perform bystander suppression (Treg) assays to confirm the suppressive effect of the CT26 self-like neo-epitopes.
- Determine if CT26 self-like neo-epitopes affect both CD4 and CD8 T cell responses.
- Efficacy studies are ongoing and will clarify the role of self-like neo-epitopes on survival.

Collaborations are welcomed!

Acknowledgments to the EpiVax and EpiVax Oncology family

EpiVax Oncology



Gad Berdugo CEO gberdugo@epivaxonco.com



Dominique Bridon CTO <u>dbridon@epivaxonco.com</u>



Guilhem Richard Lead Computational Immunologist grichard@epivaxonco.com

Annie De Groot Vaccine Research Immunoinformatics Laboratory **EpiVax** William Martin **Bethany McGonnigal** Lenny Moise Matthew Ardito Christine Boyle **Danielle Medeiros Bethany Biron** Drasti Kanakia Lenny Matt Beth B. Bill Annie Christine

Danielle

3/19/2019